Something I’ve been thinking about —
A lot of the simpler / naturally occurring peptides never seem to get real investment or approval. One angle is this: If something already exists in the body, it generally can’t be patented in its natural form. That changes the incentive completely. So you end up with:• less ownership potential• less large-scale investment• less push toward approval Curious how others see this — Do you think lack of patents is a big reason certain compounds stay in the “underground” space? Or is it something else entirely?